Post-COVID condition: dispensation of drugs and diagnostic tests as proxies of healthcare impact

被引:0
|
作者
Alessandro Nobili
Barbara D’Avanzo
Mauro Tettamanti
Alessia Antonella Galbussera
Giuseppe Remuzzi
Ida Fortino
Olivia Leoni
Sergio Harari
Pier Mannuccio Mannucci
机构
[1] Istituto di Ricerche Farmacologiche Mario Negri IRCCS,Department of Clinical Sciences and Community Health
[2] Direzione Generale Welfare,Division of Internal Medicine
[3] Regione Lombardia,undefined
[4] Università Di Milano,undefined
[5] Multimedica IRCSS,undefined
[6] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,undefined
[7] Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and University of Milan,undefined
来源
关键词
Administrative database; Clinical sequels; Long-COVID; Polypharmacy; Anticoagulants; Antipsychotic drugs; Diabetes; COPD;
D O I
暂无
中图分类号
学科分类号
摘要
With the goal to increase knowledge on the healthcare impact of the post-COVID-19 condition we exploited the administrative claims database of Lombardy, the largest Italian region and the first after China to be heavily hit by the SARS-CoV-2 pandemic in February–May 2020. We chose to employ the dispensation of drugs and diagnostic tests as proxies of the impact of the post-COVID condition in 46,574 cases who recovered from COVID-19 and were negative at PCR testing within June 20, 2020. Data were obtained throughout the 18-month post-negativization period until December 2021 and results on the use of drugs and diagnostic tests were compared with those accrued in the same cases during the pre-COVID period in July–December 2019. After an increase in the first semester after SARS-CoV-2 negativization (July–December 2020), trends in the dispensation of drugs according to the broad ATC classes and of diagnostic tests decreased or remained substantially stable. However, dispensation of drugs for acid related disorders (A02), diabetes (A10), heparins (B01AB), direct oral anticoagulants (B01AP), antipsychotics (N05A), antidepressants (N06A) and for obstructive airways diseases (R03) was still higher than in the pre-COVID period. These findings, based upon drug and diagnostic test dispensation as proxies of the healthcare impact of the post-COVID condition, show that in a substantial proportion of recovered cases the post-COVID condition is active and clinically relevant 18 months after the acute disease. The findings also provide indirect evidence of the body organs and systems more compromised in the post-COVID period.
引用
收藏
页码:801 / 809
页数:8
相关论文
共 50 条
  • [31] Maximizing public healthcare resources in the management of waiting lists post-covid
    Tobin, A. M.
    Murphy, L. A.
    O'Neill, C.
    Crealey, G.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2024,
  • [32] Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition
    Cardenas-Rodriguez, Noemi
    Ignacio-Mejia, Ivan
    Correa-Basurto, Jose
    Carrasco-Vargas, Humberto
    Vargas-Hernandez, Marco Antonio
    Albores-Mendez, Exal Manuel
    Mayen-Quinto, Rodolfo David
    de la Paz-valente, Reynita
    Bandala, Cindy
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [33] A New Professional Society for Post-COVID Condition and Other Post-Viral Conditions
    Sivan, Manoj
    Heightman, Melissa
    ADVANCES IN REHABILITATION SCIENCE AND PRACTICE, 2024, 13
  • [34] International Care programs for Pediatric Post-COVID Condition (Long COVID) and the way forward
    Brackel, Caroline L. H.
    Noij, Lieke C. E.
    Vijverberg, Susanne J. H.
    Legghe, Camille L.
    van der Zee, Anke H.
    van Goudoever, Johannes B.
    Buonsenso, Danilo
    Munblit, Daniel
    Sigfrid, Louise
    Mcfarland, Sammie
    Anmyr, Lena
    Ashkenazi-Hoffnung, Liat
    Bellinat, Ana P. N.
    Dias, Nathalia L. S.
    Edwards, Amy
    Fashina, Tomini
    Juraski, Romana Gjergja
    Goncalves, Ana L. N.
    Hansted, Edita
    Herczeg, Vivien
    Hertting, Olof
    Jankauskaite, Lina N.
    Kaswandani, Nastiti
    Kevalas, Rimantas
    Krivacsy, Peter
    Lorenz, Michael
    Malone, Laura A.
    Mcvoy, Molly
    Miller, David W.
    Morrow, Amanda K.
    Nugawela, Manjula D.
    Oliveira, Carlos R.
    Oliveira, Pablo R. S.
    Osmanov, Ismael M.
    Overmars, Isabella M.
    Paintsil, Elijah
    Pereira, Snehal M. Pinto
    Prawira, Yogi
    Putri, Nina Dwi
    Ramos, Regina C. F.
    Rasche, Marius
    Ryd-Rinder, Malin
    De Rose, Christina
    Samitova, Elmira
    Jovanovic, Tatjana Savic
    Say, Daniela
    Scott, Janet T.
    Shachar-Lavie, Iris
    Shafran, Roz
    Shmueli, Einat
    PEDIATRIC RESEARCH, 2024, 96 (02) : 319 - 324
  • [35] Barriers and opportunities for the continuous training of healthcare professionals in the post-Covid era
    Fond, G.
    Masson, M.
    Lucas, G.
    Boyer, L.
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2022, 48 (02): : 117 - 117
  • [36] Phenotyping Post-COVID Pain as a Nociceptive, Neuropathic, or Nociplastic Pain Condition
    Fernandez-de-las-Penas, Cesar
    Nijs, Jo
    Neblett, Randy
    Polli, Andrea
    Moens, Maarten
    Goudman, Lisa
    Patil, Madhura Shekhar
    Knaggs, Roger D.
    Pickering, Gisele
    Arendt-Nielsen, Lars
    BIOMEDICINES, 2022, 10 (10)
  • [37] Post-COVID condition or "long COVID", return-to work, and occupational health research
    Descatha, Alexis
    Evanoff, Bradley A.
    Fadel, Marc
    SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH, 2023, 49 (03)
  • [38] Task shifting healthcare services in the post-COVID world: A scoping review
    Das, Shukanto
    Grant, Liz
    Usher, Genevie Fernandes
    PLOS GLOBAL PUBLIC HEALTH, 2023, 3 (12):
  • [39] Impact of COVID-19 vaccination in post-COVID cardiac complications
    Parodi, Josefina B.
    Indavere, Agustin
    Jacob, Pamela Bobadilla
    Toledo, Guillermo C.
    Micali, Ruben G.
    Waisman, Gabriel
    Masson, Walter
    Epstein, Eduardo D.
    Huerin, Melina S.
    VACCINE, 2023, 41 (08) : 1524 - 1528
  • [40] Identification of post-COVID condition in a large population: a machine learning approach
    Tkt Lo
    Gary F. Teare
    Jeffrey A. Bakal
    Gavin Y. Oudit
    Kyle A. Kemp
    Hussain Usman
    Khokan C. Sikdar
    Discover Epidemics, 2 (1):